Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic capecitabine + camrelizumab + apatinib in advanced pancreatic cancer
ChiCTR2500098506Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, camrelizumab and Rivoceranib in pancreatic adenocarcinoma (PDAC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Objective response rate, Disease control rate and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
capecitabinecamrelizumabRivoceranib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500098506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098506.